Welcome to our dedicated page for GRI Bio SEC filings (Ticker: GRI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GRI Bio, Inc. (NASDAQ: GRI) SEC filings page provides access to the company’s U.S. Securities and Exchange Commission disclosures, along with AI-generated highlights to help interpret complex documents. As a clinical-stage biopharmaceutical company focused on NKT cell modulators for inflammatory, fibrotic and autoimmune diseases, GRI Bio uses its filings to report on clinical progress, financing transactions, governance matters and risk factors relevant to GRI stock.
Among the most informative documents are Form 10-K annual reports and Form 10-Q quarterly reports, which describe the company’s business, pipeline programs such as GRI-0621 for idiopathic pulmonary fibrosis and type 2 dNKT agonists for systemic lupus erythematosus, and its status as a smaller reporting and emerging growth company. These filings also summarize key agreements, intellectual property and the broader risk profile associated with clinical-stage drug development.
GRI Bio’s Form 8-K current reports highlight material events, including:
- Topline and interim data from the Phase 2a GRI-0621-IPF-02 trial in IPF, covering safety, biomarker changes, alveolar basement membrane repair markers and forced vital capacity (FVC) analyses.
- Details of public offerings of common stock, pre-funded warrants and Series F warrants, including purchase agreements, warrant terms and expected use of proceeds.
- Corporate actions such as amendments to the 2018 Equity Incentive Plan and annual meeting voting results.
On this page, users can also review registration statements on Form S-1 and amendments, which outline securities offerings and include extensive exhibit lists covering warrants, purchase agreements and other contracts. Proxy statements (DEF 14A) provide insight into board structure, compensation plans and shareholder proposals.
Stock Titan’s interface surfaces AI-powered summaries of lengthy filings to explain key points in plain language, such as how a financing may affect capital structure or how reported IPF trial data relate to GRI-0621’s development. Real-time updates from EDGAR ensure new 10-K, 10-Q, 8-K, S-1 and related forms appear promptly, while dedicated sections for insider and beneficial ownership information can be explored through the company’s broader filing history.
Use this GRI filings hub to quickly locate and interpret the regulatory documents that shape the investment narrative around GRI Bio’s NKT cell–focused pipeline and its Nasdaq-listed common stock.
GRI Bio, Inc. (GRI) reporting person Walter Marc Hertz, identified as Director and Chief Executive Officer, was granted a stock option award on 09/18/2025 covering 103,067 shares with an exercise price of $1.93 per share. The award is exercisable through 09/18/2035. Under the grant, 76,469 options vested in full on the grant date and the remaining 26,598 options vest in 12 substantially equal quarterly installments, completing on the third anniversary of the grant. The Form 4 was signed by an attorney-in-fact on 09/22/2025. The filing shows direct beneficial ownership of the options and does not include additional cash compensation or other transaction types.
Walter Marc Hertz, identified as Chief Executive Officer and a director of GRI Bio, Inc. (GRI), reported on Form 4 a transaction dated 08/26/2025 involving stock options. He acquired 26,688 shares of common stock by exercising options with an exercise price of $1.41 per share. Of the options, 17,828 vested in full on the grant date and 8,860 will vest in 12 substantially equal quarterly installments, with the option fully vested on the third anniversary of the grant date. Following the transaction, Mr. Hertz beneficially owns 26,688 shares directly. The filing is signed by an attorney-in-fact, Leanne Kelly.
David Leslie Szekeres, a director of GRI Bio, Inc. (GRI), reported receipt of a stock option award covering 10,276 shares with an exercise price of $1.41 per share. The option was granted on 08/26/2025, has an expiration date in 2035, and 6,933 of the option shares vested immediately while the remaining 3,343 shares vest in four substantially equal quarterly installments, fully vesting on the first anniversary of the grant. Following the grant, the reporting person beneficially owns 10,276 option shares on a direct basis.
GRI Bio, Inc. director David Charles Baker received a stock option grant on 08/26/2025 allowing purchase of 5,994 shares of common stock at an exercise price of $1.41 per share. Of the total, 4,044 options vested immediately on the grant date; the remaining 1,950 options vest in four substantially equal quarterly installments and will be fully vested on the one-year anniversary of the grant. The options expire on 08/26/2035. Following the grant, Mr. Baker directly beneficially owns 5,994 underlying shares from the option award.
Roelof Rongen, a director of GRI Bio, Inc. (GRI), was granted a stock option on 08/26/2025 covering 5,994 shares with an exercise price of $1.41. The option has an expiration date of 08/26/2035 and the form reports 5,994 shares beneficially owned by the reporting person following the transaction. Of the options granted, 4,044 vested in full on the grant date and 1,950 will vest in four substantially equal quarterly installments, completing vesting on the first anniversary of the grant. The Form 4 was signed by an attorney-in-fact, Leanne Kelly, on 08/26/2025.
Vipin Chaturvedi, Chief Scientific Officer of GRI Bio, Inc. (GRI), reported receipt of a stock option award dated 08/26/2025 covering 11,854 options to purchase common stock at an exercise price of $1.41 per share. Following the reported transaction, he beneficially owns 11,854 options directly. The grant vests in two parts: 7,424 options vested in full on the grant date, while 4,430 options will vest in 12 substantially equal quarterly installments and become fully vested on the third anniversary of the grant. The option expiration date is 08/26/2035. The filing was signed by an attorney-in-fact on behalf of the reporting person.
Camilla V. Simpson, a director of GRI Bio, acquired a stock option covering 5,994 shares of the issuer's common stock with an exercise price of $1.41. The option grant is exercisable beginning 08/26/2025 and expires 08/26/2035. Of the 5,994 underlying shares, 4,044 vested immediately and 1,950 vest in four substantially equal quarterly installments so the option is fully vested on the first anniversary of the grant. Following the reported transaction, Ms. Simpson beneficially owns 5,994 shares and holds them in a direct ownership form. The Form 4 was submitted by one reporting person and signed by an attorney-in-fact.
GRI Bio, Inc. reported a Form 4 showing that Chief Financial Officer Leanne Kelly was granted a stock option on 08/26/2025 to purchase 11,854 shares of common stock at an exercise price of $1.41 per share. The option becomes exercisable immediately for 7,424 shares while the remaining 4,430 shares vest in 12 substantially equal quarterly installments, fully vesting on the third anniversary of the grant. The option expires on 08/26/2035. Following the transaction, Ms. Kelly beneficially owns 11,854 options directly.
GRI Bio, Inc. filed a current report to make a new corporate presentation available to the market. The company is furnishing, rather than filing, this information under Regulation FD, which means the materials are provided for informational purposes and are not subject to certain liability provisions of the Exchange Act. The 8-K identifies the presentation as Exhibit 99.1, titled "GRI Bio, Inc. Corporate Presentation" and dated August 20, 2025.
GRI Bio, Inc. director Camilla V. Simpson was granted a stock option on 08/13/2025 to buy 4,527 shares of common stock at an exercise price of $1.30 per share. The option appears in Table II as a derivative security with an expiration date of 08/13/2035. The filing states the option vests in four equal quarterly installments and is fully vested on the first anniversary of the grant date. The reporting person is shown as a director and the Form 4 was signed by an attorney-in-fact on 08/14/2025.
FAQ
What is the current stock price of GRI Bio (GRI)?
What is the market cap of GRI Bio (GRI)?
